SCHEMBL13630997

SCHEMBL13630997

CC(C)CN(C[C@H]1OC(C)(C)N(C(=O)O[C@H]2CO[C@H]3OCC[C@H]32)[C@H]1Cc1ccc(OCc2ccccc2C#N)cc1)S(=O)(=O)c1ccc2c(c1)OCO2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.50
KCNE1 P15382 1/20 0.40
KCNQ1 P51787 1/20 0.40
KCNH2 Q12809 1/20 0.40
SCN5A Q14524 1/20 0.40
KCND3 Q9UK17 1/20 0.40
MMP1 P03956 3/20 0.35
ADAM17 P78536 2/20 0.35
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
MAOB P27338 1/20 0.33
ADAMTS4 O75173 1/20 0.32
MMP13 P45452 1/20 0.32
ALDH1A1 P00352 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
CASP3 P42574 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13630859 0.93 ABCB1 (0.47) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL6051158 0.92 ABCB1 (0.51) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL6051160 0.92 ABCB1 (0.51) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL13617983 0.92 ABCB1 (0.52) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL13617984 0.92 ABCB1 (0.49) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL13630860 0.91 ABCB1 (0.50) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL6060847 0.90 ABCB1 (0.49) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL13630993 0.90 ABCB1 (0.52) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL13630854 0.89 ABCB1 (0.52) ABCB1KCNE1KCNQ1KCNH2SCN5A
SCHEMBL13631052 0.89 ABCB1 (0.52) ABCB1KCNE1KCNQ1KCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 ABCB1 628/4885KCNE1 3515/4885KCNQ1 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.